Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

The widely used chemotherapy cisplatin causes permanent hearing loss in 40%–60% of patients with cancer. One drug, sodium thiosulfate, is approved by the FDA for use in pediatric patients with localized solid tumors for preventing cisplatin-induced hearing loss, but more drugs are desperately needed...

Full description

Bibliographic Details

Published in:	JCI Insight
Main Authors:	Matthew A. Ingersoll, Richard D. Lutze, Chithra K. Pushpan, Regina G. Kelmann, Huizhan Liu, Mark T. May, William J. Hunter, David Z.Z. He, Tal Teitz
Format:	Article
Language:	English
Published:	American Society for Clinical investigation 2023-12-01
Subjects:	Otology Therapeutics
Online Access:	https://doi.org/10.1172/jci.insight.171140